Literature DB >> 24452790

FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system.

Chen Huang1, Dacheng Xie, Jiujie Cui, Qi Li, Yong Gao, Keping Xie.   

Abstract

PURPOSE: The transcription factor Forkhead box M1 (FOXM1) plays important roles in the formation of several human tumors, including pancreatic cancer. However, the molecular mechanisms by which FOXM1 promotes pancreatic tumor epithelial-to-mesenchymal transition (EMT) and metastasis are unknown. EXPERIMENTAL
DESIGN: The effect of altered expression of FOXM1 and urokinase-type plasminogen activator receptor (uPAR) on EMT and metastasis was examined using animal models of pancreatic cancer. Also, the underlying mechanisms of altered pancreatic cancer invasion and metastasis were analyzed using in vitro molecular biology assays. Finally, the clinical relevance of dysregulated FOXM1/uPAR signaling was investigated using pancreatic tumor and normal pancreatic tissue specimens.
RESULTS: Pancreatic tumor specimens and cell lines predominantly overexpressed the FOXM1 isoform FOXM1c. FOXM1c overexpression promoted EMT in and migration, invasion, and metastasis of pancreatic cancer cells, whereas downregulation of FOXM1 expression inhibited these processes. The level of FOXM1 expression correlated directly with that of uPAR expression in pancreatic cancer cell lines and tumor specimens. Moreover, FOXM1c overexpression upregulated uPAR expression in pancreatic cancer cells, whereas inhibition of FOXM1 expression suppressed uPAR expression. Furthermore, transfection of FOXM1c into pancreatic cancer cells directly activated the uPAR promoter, whereas inhibition of FOXM1 expression by FOXM1 siRNA suppressed its activation in these cells. Finally, we identified an FOXM1-binding site in the uPAR promoter and demonstrated that FOXM1 protein bound directly to it. Deletion mutation of this site significantly attenuated uPAR promoter activity.
CONCLUSIONS: Our findings demonstrated that FOXM1c contributes to pancreatic cancer development and progression by enhancing uPAR gene transcription, and thus, tumor EMT and metastasis. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24452790      PMCID: PMC3959252          DOI: 10.1158/1078-0432.CCR-13-2311

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

1.  FOXM1c transactivates the human c-myc promoter directly via the two TATA boxes P1 and P2.

Authors:  Inken Wierstra; Jürgen Alves
Journal:  FEBS J       Date:  2006-09-11       Impact factor: 5.542

2.  FOXM1c is activated by cyclin E/Cdk2, cyclin A/Cdk2, and cyclin A/Cdk1, but repressed by GSK-3alpha.

Authors:  Inken Wierstra; Jürgen Alves
Journal:  Biochem Biophys Res Commun       Date:  2006-07-12       Impact factor: 3.575

3.  STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo.

Authors:  Chen Huang; Tao Jiang; Lin Zhu; Jun Liu; Jun Cao; Ke-Jian Huang; Zheng-Jun Qiu
Journal:  Int J Oncol       Date:  2011-04-08       Impact factor: 5.650

4.  Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells.

Authors:  Zhiwei Wang; Sanjeev Banerjee; Dejuan Kong; Yiwei Li; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

5.  The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer.

Authors:  Il-Man Kim; Timothy Ackerson; Sneha Ramakrishna; Maria Tretiakova; I-Ching Wang; Tanya V Kalin; Michael L Major; Galina A Gusarova; Helena M Yoder; Robert H Costa; Vladimir V Kalinichenko
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

Review 6.  Pancreatic cancer: current and future treatment strategies.

Authors:  K Pliarchopoulou; D Pectasides
Journal:  Cancer Treat Rev       Date:  2009-03-27       Impact factor: 12.111

Review 7.  The urokinase plasminogen activator system: a target for anti-cancer therapy.

Authors:  Salvatore Ulisse; Enke Baldini; Salvatore Sorrenti; Massimino D'Armiento
Journal:  Curr Cancer Drug Targets       Date:  2009-02       Impact factor: 3.428

8.  Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis.

Authors:  D W Chan; S Y M Yu; P M Chiu; K M Yao; V W S Liu; A N Y Cheung; H Y S Ngan
Journal:  J Pathol       Date:  2008-07       Impact factor: 7.996

9.  Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain.

Authors:  K M Yao; M Sha; Z Lu; G G Wong
Journal:  J Biol Chem       Date:  1997-08-08       Impact factor: 5.157

10.  Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.

Authors:  Shashi R Harvey; Thelma C Hurd; Gabor Markus; Maisie I Martinick; Remedios M Penetrante; Dongfeng Tan; Preeti Venkataraman; Nisha DeSouza; Sheila N J Sait; Deborah L Driscoll; John F Gibbs
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

View more
  42 in total

1.  Integrated analysis of transcription factor, microRNA and LncRNA in an animal model of obliterative bronchiolitis.

Authors:  Ming Dong; Xin Wang; Hong-Lin Zhao; Xing-Long Chen; Jing-Hua Yuan; Jiu-Yi Guo; Ke-Qiu Li; Guang Li
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis.

Authors:  Chen Huang; Jiawei Du; Keping Xie
Journal:  Biochim Biophys Acta       Date:  2014-01-11

3.  Tight correlation between FoxM1 and FoxP3+ Tregs in gastric cancer and their clinical significance.

Authors:  Xiaoxiao Li; Kai Ma; Shanai Song; Fangzhen Shen; Tao Kuang; Yingqian Zhu; Zimin Liu
Journal:  Clin Exp Med       Date:  2018-05-26       Impact factor: 3.984

4.  UCHL3 promotes pancreatic cancer progression and chemo-resistance through FOXM1 stabilization.

Authors:  Zhiwang Song; Junhe Li; Ling Zhang; Jun Deng; Ziling Fang; Xiaojun Xiang; Jianping Xiong
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

5.  MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC).

Authors:  Jiali Zhang; Yu Wang; Xinming Chen; Yi Zhou; Fangyan Jiang; Jirong Chen; Li Wang; Wen-Feng Zhang
Journal:  Oncotarget       Date:  2015-04-10

6.  Protein-DNA array-based identification of transcription factor activities differentially regulated in obliterative bronchiolitis.

Authors:  Ming Dong; Xin Wang; Hong-Lin Zhao; Yu-Xia Zhao; Ya-Qing Jing; Jing-Hua Yuan; Yi-Jiu Guo; Xing-Long Chen; Ke-Qiu Li; Guang Li
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

7.  Overexpression of forkhead Box C2 promotes tumor metastasis and indicates poor prognosis in colon cancer via regulating epithelial-mesenchymal transition.

Authors:  Qingguo Li; Jitao Wu; Ping Wei; Ye Xu; Changhua Zhuo; Yuwei Wang; Dawei Li; Sanjun Cai
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

8.  Quantitative proteomic analysis identifies new effectors of FOXM1 involved in breast cancer cell migration.

Authors:  Xiaojuan Ye; Yi Zhang; Bin He; Yuesheng Meng; Yandong Li; Yong Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 9.  Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.

Authors:  Tasuku Matsuoka; Masakazu Yashiro
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

10.  Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.

Authors:  Marie K Gurka; Dillon Pender; Phillip Chuong; Benjamin L Fouts; Alexander Sobelov; Molly W McNally; Megan Mezera; Shiao Y Woo; Lacey R McNally
Journal:  J Control Release       Date:  2016-01-05       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.